Erratum: WTAP is a novel oncogenic protein in acute myeloid leukemia

Bansal, Hima; Yihua, Q.; Iyer, Swaminathan P.; Ganapathy, Suthakar; Proia, David A.; Penalva, Luiz O. F.; Uren, Philip J.; Suresh, Uthra; Carew, Jennifer S.; Karnad, Anand B.; Weitman, Steven; Tomlinson, Gail E.; Rao, Manjeet K.; Kornblau, Steven M.; Bansal, Sanjay

doi:10.1038/leu.2014.290

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, METTL14 also functions as an oncogene in the self-renewal of leukemia stem cells (LSCs) and AML maintenance via an m 6 A-meditated MYB/MYC-dependent regulatory pathway (Weng et al 2018). Additionally, other methyltransferase components such as WTAP and RBM15 are also implicated in leukemogenesis, while its association with m 6 A remains to be elucidated (Bansal et al 2014;Ma et al 2001). FTO is significantly upregulated in AMLs with t(11q23)/MLL rearrangements, t(15;17)/PML-RARA, FLT3-ITD, and/or NPM1 mutations, and exerts an oncogenic role in AML by post-transcriptionally downregulating expression of critical transcripts such as ASB2 and RARA through m 6 A demethylation activity (Li et al 2017b).…”

Section: Rna Methylation Functions In Cancermentioning

confidence: 99%

RNA methylation in mammalian development and cancer

et al. 2021

View full text Add to dashboard Cite

Similar to epigenetic DNA and histone modifications, epitranscriptomic modifications (RNA modifications) have emerged as crucial regulators in temporal and spatial gene expression during eukaryotic development. To date, over 170 diverse types of chemical modifications have been identified upon RNA nucleobases. Some of these post-synthesized modifications can be reversibly installed, removed, and decoded by their specific cellular components and play critical roles in different biological processes. Accordingly, dysregulation of RNA modification effectors is tightly orchestrated with developmental processes. Here, we particularly focus on three well-studied RNA modifications, including N6-methyladenosine (m6A), 5-methylcytosine (m5C), and N1-methyladenosine (m1A), and summarize recent knowledge of underlying mechanisms and critical roles of these RNA modifications in stem cell fate determination, embryonic development, and cancer progression, providing a better understanding of the whole association between epitranscriptomic regulation and mammalian development.

show abstract

Section: Rna Methylation Functions In Cancermentioning

confidence: 99%

RNA methylation in mammalian development and cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

Physio-pathological effects of N6-methyladenosine and its therapeutic implications in leukemia

2022

View full text Add to dashboard Cite

N6-methyladenosine (m6A), the most prevalent epigenetic modification of RNA in mammals, has become a hot topic throughout recent years. m6A is involved with every links of the RNA fate, including RNA splicing, nuclear export, translation and stability. Due to the reversible and dynamic regulatory network composed of ‘writers’ (methylase), ‘erasers’ (demethylase) and ‘readers’ (m6A binding proteins), m6A has been deemed as an essential modulator in vast physiological and pathological processes. Previous studies have shown that aberrant expression and dysfunction of these regulators are implicated in diverse tumors, exemplified by hematological malignancies. However, we should hold a dialectic perspective towards the influence of m6A modification on leukemogenesis. Given that m6A itself is neither pro-oncogenic nor anti-oncogenic, whether the modifications promote hematological homeostasis or malignancies occurrence and progression is dependent on the specific targets it regulates. Ample evidence supports the role of m6A in maintaining normal hematopoiesis and leukemogenesis, thereby highlighting the therapeutic potential of intervention in m6A modification process for battling leukemia. In this review, we introduce the advances of m6A modification and summarize the biological functions of m6A in RNA metabolism. Then we discuss the significance of several well-studied m6A regulators in modulating normal and malignant hematopoiesis, with focus on the therapeutic potentials of targeting these regulators for battling hematopoietic malignancies.

show abstract

Emerging function of N6‑methyladenosine in cancer (Review)

Hong

2018

Oncol Lett

View full text Add to dashboard Cite

N6-methyladenosine (m6A) modification in RNA has been implicated in diverse biological processes including the maintenance of embryonic stem cells, early development and diseases. Although the m6A modification was discovered several decades ago, its biological function remained unclear. The recent discovery of enzymes responsible for 'writing' or 'erasing' the modification and single-nucleotide resolution mapping by next-generation sequencing technology have revealed its function in biological processes. Its enrichment pattern is conserved in mammalian transcriptomes, and the level of m6A is tightly regulated by methyltransferases (writers), demethylases (erasers) and binding proteins (readers). Furthermore, accumulating evidence suggests that the aberrant regulation of m6A turnover is associated with multiple types of cancer including acute myeloid leukemia, breast cancer, glioblastoma, lung cancer and liver cancer. Studies have demonstrated that factors involved in m6A metabolism serve either oncogenic or tumor-suppressor roles in different contexts. The previous studies of the role of m6A in cancer biology are discussed in the present review. Contents 1. Introduction 2. m6A enrichment and its function 3. Factors metabolizing m6A 4. Role of m6A in cancer 5. Perspectives

show abstract

Erratum: WTAP is a novel oncogenic protein in acute myeloid leukemia

Cited by 3 publications

References 0 publications

RNA methylation in mammalian development and cancer

RNA methylation in mammalian development and cancer

Physio-pathological effects of N6-methyladenosine and its therapeutic implications in leukemia

Emerging function of N6‑methyladenosine in cancer (Review)

Contact Info

Product

Resources

About